JNJ vs LLY
Johnson & Johnson and ELI Lilly & Co., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | JNJ | LLY |
|---|---|---|
| Revenue | $94.2B | $65.2B |
| Net income | $26.8B | $20.6B |
| Gross margin | 67.9% | 83.0% |
| Net margin | 28.5% | 31.7% |
| Return on equity | — | 101.2% |
| Diluted EPS | $11.03 | $22.95 |
| Dividend / share | $5.14 | $6.23 |
| Payout ratio | — | 26.1% |
| Free cash flow | $19.7B | — |
| Equity | — | $26.5B |
| Net debt / equity | — | 1.33× |
| Current ratio | 1.03× | 1.58× |
| Revenue CAGR 5y | 2.7% | 21.6% |
| Profit CAGR 5y | 12.7% | 27.2% |
JNJ bills 1.4× the revenue of LLY, and LLY keeps more of each dollar of revenue as profit (31.7% against 28.5%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | JNJ | LLY |
|---|---|---|
| FY2025 | $94.2B | $65.2B |
| FY2024 | $88.8B | $45.0B |
| FY2023 | $85.2B | $34.1B |
| FY2022 | $80.0B | $28.5B |
| FY2021 | $78.7B | $28.3B |
| FY2020 | $82.6B | $24.5B |
| FY2019 | $82.1B | $22.3B |
| FY2018 | $81.6B | $21.5B |
| FY2017 | $76.5B | $20.0B |
| FY2016 | $71.9B | $21.2B |
Net income by year
Bottom line
| Fiscal year | JNJ | LLY |
|---|---|---|
| FY2025 | $26.8B | $20.6B |
| FY2024 | $14.1B | $10.6B |
| FY2023 | $35.2B | $5.2B |
| FY2022 | $17.9B | $6.2B |
| FY2021 | $20.9B | $5.6B |
| FY2020 | $14.7B | $6.2B |
| FY2019 | $15.1B | $8.3B |
| FY2018 | $15.3B | $3.2B |
| FY2017 | $1.3B | $-204.1M |
| FY2016 | $16.5B | $2.7B |
Advertisement
AdSense · Rectangle 336×280